DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
- Status
- UNKNOWN
- Phase
- PHASE2
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
- Status
- TERMINATED
- Phase
- PHASE2
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE3
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
- Status
- TERMINATED
- Phase
- PHASE2
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
- Status
- COMPLETED
- Phase
- NA
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
- Status
- TERMINATED
- Phase
- PHASE2
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Status
- RECRUITING
- Phase
- PHASE1
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE2
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
- Status
- TERMINATED
- Phase
- PHASE2
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
- Status
- WITHDRAWN
- Phase
- NA